Qiagen N.V.

NYSE:QGEN

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🔬 Clinical Trials

🩺 Medical Instruments

Location

Netherlands

Market Cap

USD 10.13 B

Share Price

USD 46.76

Avg Daily Volume

1,514,744

Change (1 day)

0.45%

Change (1 year)

11.63%

Change (YTD)

5.01%

Qiagen N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD 372.10 M

Qiagen N.V. EBITDA is USD 372.10 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -43.49% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Qiagen N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 658.40 M, a -3.39% change year over year.
Qiagen N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 681.47 M, a -25.49% change year over year.
Qiagen N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 914.57 M, a -1.79% change year over year.
Qiagen N.V. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 931.20 M, a 275.61% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NYSE: QGEN

Qiagen N.V.

CEO	Mr. Thierry Bernard
IPO Date	June 28, 1996
Location	Netherlands
Headquarters	Hulsterweg 82
Employees	5,700
Sector	🏥 Health Care
Industries Biotechnology 🔬 Chemicals & Advanced Materials 🔬 Clinical Trials 🩺 Medical Instruments

Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.